{"id":"dexlansoprazole-based-triple-therapy","safety":{"commonSideEffects":[{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Abdominal pain"},{"rate":null,"effect":"Taste disturbance"}]},"_chembl":{"chemblId":"CHEMBL1201863","moleculeType":"Small molecule","molecularWeight":"369.37"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Dexlansoprazole reduces intragastric acid production, creating an environment where antibiotics (typically amoxicillin and clarithromycin or metronidazole) can more effectively eliminate H. pylori bacteria. The combination therapy addresses both acid suppression and bacterial eradication, improving cure rates for peptic ulcer disease and H. pylori-associated conditions.","oneSentence":"Dexlansoprazole is a proton pump inhibitor that suppresses gastric acid secretion by blocking H+/K+-ATPase in parietal cells; in triple therapy it is combined with antibiotics to eradicate Helicobacter pylori infection.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:44:25.972Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Helicobacter pylori eradication as part of triple therapy"},{"name":"Peptic ulcer disease associated with H. pylori infection"}]},"trialDetails":[{"nctId":"NCT07344506","phase":"PHASE4","title":"CURE-H. Pylori: A Trial on the Combination of Anti-Ulcerants and Levofloxacin-Based Therapy for Helicobacter Pylori Eradication","status":"RECRUITING","sponsor":"Dow University of Health Sciences","startDate":"2025-05-01","conditions":"H. Pylori Gastrointestinal Disease, H.Pylori Infection, H.Pylori Eradication Rate","enrollment":942},{"nctId":"NCT06964334","phase":"PHASE3","title":"The Effect of Vitamin D Supplement as Adjuvant Therapy in Eradication of Helicobacter Pylori Infection","status":"NOT_YET_RECRUITING","sponsor":"Assiut University","startDate":"2025-06-01","conditions":"Helicobacter Pylori Infection","enrollment":70},{"nctId":"NCT05371249","phase":"PHASE4","title":"Vonoprazan-Based Triple Therapy in Comparison With Extended Sequential Therapy","status":"UNKNOWN","sponsor":"Fu Jen Catholic University Hospital","startDate":"2021-12-01","conditions":"Helicobacter Pylori","enrollment":628},{"nctId":"NCT04713670","phase":"PHASE4","title":"Comparison of Vonoprazan-based Versus Lansoprazole-based Triple Therapy, High Dose Dual Therapy, Bismuth and Non-bismuth Quadruple Therapy in the First-line Treatment of Helicobacter Pylori Infection","status":"RECRUITING","sponsor":"National Taiwan University Hospital","startDate":"2021-03-10","conditions":"H. Pylori Infection","enrollment":1200},{"nctId":"NCT05184491","phase":"PHASE4","title":"Nitazoxanide and Lansoprazole Based Regimens for H. Pylori Management","status":"UNKNOWN","sponsor":"National Liver Institute, Egypt","startDate":"2021-10-15","conditions":"Helicobacter Pylori","enrollment":500},{"nctId":"NCT02557932","phase":"PHASE3","title":"Comparison of 7-day PPI-based Standard Triple Therapy and 10-day Bismuth Quadruple Therapy for H. Pylori Eradication","status":"COMPLETED","sponsor":"National Cancer Center, Korea","startDate":"2015-09","conditions":"Helicobacter Pylori Infection, Family History of Stomach Cancer","enrollment":352},{"nctId":"NCT03571230","phase":"PHASE4","title":"Antimicrobial Susceptibility Testing Guided Therapy Versus Empirical Therapy for the First-line Helicobacter Pylori Eradication.","status":"UNKNOWN","sponsor":"Shandong University","startDate":"2018-07-01","conditions":"Helicobacter Pylori Infection, Antimicrobial Susceptibility Testing","enrollment":400},{"nctId":"NCT01906879","phase":"PHASE4","title":"Triple Therapy Versus Quadruple Therapies in the First Line Therapy of Helicobacter Pylori Infection","status":"UNKNOWN","sponsor":"National Taiwan University Hospital","startDate":"2013-06","conditions":"Helicobacter Pylori Infection","enrollment":1620},{"nctId":"NCT02726269","phase":"PHASE3","title":"Triple Therapy Versus Levofloxacin-based Therapy for Helicobacter Pylori Eradication in Mexico.","status":"COMPLETED","sponsor":"Asofarma de México S.A de C.V.","startDate":"2012-06","conditions":"Helicobacter Pylori Gastritis","enrollment":230},{"nctId":"NCT02682446","phase":"","title":"The Efficacy of Serum Pepsinogen for Prediction of Metachronous Gastric Neoplasm","status":"COMPLETED","sponsor":"Kyungpook National University Hospital","startDate":"2007-01","conditions":"Gastric Cancer","enrollment":800},{"nctId":"NCT02541786","phase":"PHASE4","title":"Comparison of Dexlansoprazole-based Triple and Rabeprazole-based Triple Therapies for Helicobacter Pylori Infection","status":"COMPLETED","sponsor":"Kaohsiung Medical University","startDate":"2015-01","conditions":"Helicobacter Pylori Infection","enrollment":177},{"nctId":"NCT01888237","phase":"PHASE4","title":"High Dose PPI Triple Therapy Versus Sequential Therapy for Helicobacter Pylori Eradication","status":"COMPLETED","sponsor":"Mahidol University","startDate":"2013-05","conditions":"Dyspepsia, Helicobacter-associated Gastritis, Stomach Disorders","enrollment":118},{"nctId":"NCT01537055","phase":"PHASE4","title":"Comparison of the Efficacy of Levofloxacin-based Sequential Therapy and Triple Therapy as Second Line Therapy","status":"UNKNOWN","sponsor":"National Taiwan University Hospital","startDate":"2012-02","conditions":"Eradication Rate for Helicobacter","enrollment":600},{"nctId":"NCT01607918","phase":"PHASE4","title":"Clarithromycin-based Triple Therapy for 14 Days Versus Sequential Therapy 10 Days in the First Line Therapy","status":"UNKNOWN","sponsor":"National Taiwan University Hospital","startDate":"2012-02","conditions":"Eradication Rates of the Two Regimens","enrollment":1300},{"nctId":"NCT00816140","phase":"PHASE4","title":"Levofloxacin Versus Clarithromycin Triple Therapy in First-Line Treatment for Helicobacter Pylori Eradication","status":"COMPLETED","sponsor":"National Taiwan University Hospital","startDate":"2007-06","conditions":"Helicobacter Infections","enrollment":432}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":4,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Dexilant-based triple therapy"],"phase":"marketed","status":"active","brandName":"dexlansoprazole based triple therapy","genericName":"dexlansoprazole based triple therapy","companyName":"Kaohsiung Medical University","companyId":"kaohsiung-medical-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Dexlansoprazole is a small molecule inhibitor of the potassium-transporting ATPase, used in triple therapy for the eradication of Helicobacter pylori infections. This triple therapy typically involves a combination of dexlansoprazole, clarithromycin, and amoxicillin, and is studied for its effectiveness in treating conditions such as Helicobacter pylori gastritis and gastric cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}